Lund November 2, 2020. Hansa Biopharma today announced that the Nomination Committee has been formed in accordance with the principles adopted by the Annual General Meeting (AGM) on June 23, 2020 and has the following composition:
· Natalie Berner representing Redmile Group
· Thomas Olausson
· Jannis Kitsakis representing AP4
· Ulf Wiinberg, Chairman of the Board
The Chairman of the Board shall also summon the first meeting of the Nomination Committee.
The function of the Nomination Committee is to prepare and submit proposals for the AGM regarding the number of board members to be elected by the general meeting, election of chairman and other board members, board fees and any remuneration for committee work, election of the chairman of the AGM, election of auditors (if applicable) and fee for the auditors, and proposals for rules for appointing the Nomination Committee.
The proposals of the Nomination Committee will be presented in the notice of the Annual General Meeting 2021 and will be published on Hansa Biopharma's website.
Shareholders wishing to submit comments or proposals to the Nomination Committee may do so via e-mail to email@example.com or by letter to Hansa Biopharma, Nomination Committee, Box 785, 220 07 Lund, Sweden.
This is information that Hansa Biopharma AB is obliged to make public pursuant to the EU Market Abuse Regulation.
For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Mobile: +46 (0) 709-298 269
Head of Corporate Communications
Mobile: +46 (0) 768-198 326
About Hansa Biopharma
Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, gene therapy and cancer. The Company's lead product candidate, imlifidase, is an antibody cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. Imlifidase has been granted conditional approval in the European Union for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Commercial launch in select European countries is expected in the fourth quarter of 2020. Hansa's research and development program is advancing the Company's enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases, gene therapy and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in other European countries and in the U.S.
(c) 2020 Cision. All rights reserved., source Press Releases - English